Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs
暂无分享,去创建一个
[1] W. J. Oakes,et al. Preliminary Observations on the Association between Simple Metopic Ridging in Children without Trigonocephaly and the Chiari I Malformation , 2001, Pediatric Neurosurgery.
[2] D. Rampton,et al. Gut pH and transit time in ulcerative colitis appear sufficient for complete dissolution of pH-dependent 5-ASA-containing capsules , 2000 .
[3] J. Fallingborg,et al. Intraluminal pH of the human gastrointestinal tract. , 1999, Danish medical bulletin.
[4] V. Annese,et al. Prevention of post‐operative recurrence of Crohn’s disease requires adequate mucosal concentration of mesalazine , 1999, Alimentary pharmacology & therapeutics.
[5] Taylor,et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months , 1998, Alimentary pharmacology & therapeutics.
[6] A. Lavy,et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. , 1998, Gastroenterology.
[7] D. Jewell,et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. , 1998, The New England journal of medicine.
[8] D. Jewell,et al. A Comparison of Budesonide and Mesalamine for Active Crohn's Disease , 1998 .
[9] Press,et al. Gastrointestinal pH profiles in patients with inflammatory bowel disease , 1998, Alimentary pharmacology & therapeutics.
[10] A. Lobo,et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. , 1998, Gastroenterology.
[11] M. Cottone,et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. , 1997, Gastroenterology.
[12] M. Veysey,et al. IS Cholelithiasis an Intestinal Disease? a Study of Five Inter-Related Factors , 1997 .
[13] A. Zinsmeister,et al. A Dose‐Ranging Study of Azathioprine Pharmacokinetics After Single‐Dose Administration of a Delayed‐Release Oral Formulation , 1997, Journal of clinical pharmacology.
[14] A. Munakata,et al. Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease. , 1997, The American journal of gastroenterology.
[15] A. Light,et al. Mucosal enzyme activity for butyrate oxidation; no defect in patients with ulcerative colitis. , 1996, Gut.
[16] H. Möllmann,et al. Glucocorticoid therapy in chronic inflammatory bowel disease : from basic principles to rational therapy , 1996 .
[17] G. Fick,et al. Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.
[18] R. Fedorak,et al. Budesonide‐β‐D‐glucuronide: A Potential Prodrug for Treatment of Ulcerative Colitis , 1995 .
[19] H. Hove,et al. Butyrate absorption and lactate secretion in ulcerative colitis , 1995, Diseases of the colon and rectum.
[20] R. Fedorak,et al. Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. , 1995, Journal of pharmaceutical sciences.
[21] G. Fick,et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.
[22] A. Zinsmeister,et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. , 1994, Journal of clinical gastroenterology.
[23] D. Jewell,et al. A comparison of budesonide with prednisolone for active Crohn's disease. , 1994, The New England journal of medicine.
[24] J. Fallingborg,et al. Comparative bioavailability of 5‐aminosalicylic acid from a controlled release preparation and an azo‐bond preparation , 1994, Alimentary pharmacology & therapeutics.
[25] D. Jewell,et al. Salicylates for inflammatory bowel disease. , 1994, Bailliere's clinical gastroenterology.
[26] Boyle,et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. , 1994, Gut.
[27] I. Finnie,et al. Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism. , 1993, Gut.
[28] J. Teare,et al. The mode of action of the aminosalicylates in inflammatory bowel disease , 1993 .
[29] S. Hanauer,et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.
[30] G. May,et al. Sulfasalazine Revisited , 1993, Annals of Internal Medicine.
[31] R. P. Thompson,et al. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. , 1993, Alimentary pharmacology & therapeutics.
[32] M. Rijk,et al. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. , 1992, Scandinavian journal of gastroenterology.
[33] V. Trimble,et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis , 1992, The Lancet.
[34] I. Mena,et al. Colonic motility and transit in health and ulcerative colitis. , 1991, Gastroenterology.
[35] J. Rask-Madsen,et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. , 1990, Gut.
[36] S. Hansen,et al. Topical and systemic availability of 5‐amino‐salicylate: comparisons of three controlled release preparations in man , 1990, Alimentary pharmacology & therapeutics.
[37] L. A. Christensen,et al. pH‐Profile and regional transit times of the normal gut measured by a radiotelemetry device , 1989, Alimentary pharmacology & therapeutics.
[38] R. V. van Hogezand,et al. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. , 1989, Scandinavian journal of gastroenterology.
[39] U. Klotz,et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. , 1989, Gastroenterology.
[40] R. Caprilli,et al. Fecal lactate and ulcerative colitis. , 1988, Gastroenterology.
[41] S. Riley,et al. Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects. , 1988, British journal of clinical pharmacology.
[42] J. Hardcastle,et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. , 1988, Gut.
[43] D. Jewell,et al. Studies on the acetylating capacity of human colonic epithelial cells for 5-aminosalicylic acid. , 1988, Scandinavian journal of gastroenterology. Supplement.
[44] N. Read,et al. Studies on the mechanism of bowel disturbance in ulcerative colitis. , 1987, Gastroenterology.
[45] C. Deighton,et al. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. , 1987, Gut.
[46] J. Wager,et al. Mucosal surface pH of the large intestine of the rat and of normal and inflamed large intestine in man. , 1987, Gut.
[47] S. Hansen,et al. Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. , 1987, British journal of clinical pharmacology.
[48] A. Richens,et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. , 1987, Gut.
[49] R. Caprilli,et al. Faecal excretion of bicarbonate in ulcerative colitis. , 1986, Digestion.
[50] D. Faegenburg,et al. Intestinal obstruction caused by ingestion of a Heidelberg capsule: report of a case. , 1985, The American journal of gastroenterology.
[51] W. Roediger,et al. Colonic bicarbonate output as a test of disease activity in ulcerative colitis. , 1984, Journal of clinical pathology.
[52] R. Ryder,et al. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis. , 1983, British journal of clinical pharmacology.
[53] S. Hansen,et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. , 1982, Gastroenterology.
[54] S. Truelove,et al. Luminal ions and short chain fatty acids as markers of functional activity of the mucosa in ulcerative colitis. , 1982, Journal of clinical pathology.
[55] J. Cummings. The Large Intestine. Its Role in Mammalian Nutrition and Homeostasis , 1981 .
[56] B W Watson,et al. An accurate, long-term, pH-sensitive radio pill for ingestion and implantation. , 1981, Biotelemetry and patient monitoring.
[57] W. Roediger,et al. THE COLONIC EPITHELIUM IN ULCERATIVE COLITIS: AN ENERGY-DEFICIENCY DISEASE? , 1980, The Lancet.
[58] J. Cummings,et al. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. , 1979, The American journal of clinical nutrition.
[59] S. Truelove,et al. AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.
[60] A. Dawson,et al. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device , 1974, Gut.
[61] O. Wrong,et al. The interrelations of faecal ammonia, pH and bicarbonate: evidence of colonic absorption of ammonia by non-ionic diffusion. , 1972, Clinical science.
[62] S. Meldrum,et al. pH profile of gut as measured by radiotelemetry capsule. , 1972, British medical journal.
[63] R. Prescott,et al. Faecal stasis and diverticular disease in ulcerative colitis , 1970, Gut.
[64] O. Wrong,et al. In vivo dialysis of faeces as a method of stool analysis. IV. The organic anion component. , 1969, Clinical science.
[65] S. Salem,et al. Upper intestinal motility in ulcerative colitis, idiopathic steatorrhoea, and the irritable colon syndrome. , 1965, Gut.
[66] J. H. Baron,et al. CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS , 1965 .
[67] O. Manousos,et al. Abnormal motility of the small intestine in ulcerative colitis. , 1965, Gastroenterologia.
[68] S. Truelove,et al. Comparison of Corticosteroid and Sulphasalazine Therapy in Ulcerative Colitis , 1962, British medical journal.
[69] J. Lennard-jones,et al. Faecal stasis in proctocolitis , 1962, Gut.